Edura Pharmaceuticals Private Limited

Edura Pharmaceuticals Private Limited - pharma in New Delhi, Delhi, India. FY 2026 financials & compliance.
CIN U52311DL2010PTC206871 Incorporated 09 August 2010 ROC Delhi HQ New Delhi, Delhi, India
Active Private Limited Company pharma MSME · Micro
Revenue · FY 2025
₹5.55 Cr
▼ 14% YoY
Net profit · FY 2025
₹50.84 Lakh
Net margin 9.2%
EBITDA · FY 2025
₹99.14 Lakh
EBITDA margin 17.9%
Authorised capital
₹5 Lakh
Registered with MCA
Paid-up capital
₹5 Lakh
Issued & subscribed
Open charges
₹40.5 Lakh
Secured borrowings
Company age
16 yrs
Est. 2010
Directors on board
3
As per MCA filings

About Edura Pharmaceuticals Private Limited

Data last updated:

Edura Pharmaceuticals Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 09 August 2010 and has been in existence for over 16 years.

The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U52311DL2010PTC206871. Its GSTIN is 07AACCE4729P1Z7 (Delhi). The company holds 2 GST registrations, all of them active.

The company has an authorised share capital of ₹5 Lakh and a paid-up capital of ₹5 Lakh. It is led by directors including Vikas Gambhir and Vikas.

Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at C – 8/144 Pkt – 8 Sector – 8 Rohini, New Delhi, Delhi, India – 110085.

As per the financials filed for FY 2025, the company reported a revenue of ₹5.55 Cr, a decline of 14% compared to the previous year. For the same year it recorded a net profit of ₹50.84 Lakh (net margin 9.2%) and EBITDA of ₹99.14 Lakh (EBITDA margin 17.9%). Revenue has grown at a compounded annual rate (CAGR) of 9% over three years and 1% over five years.

As per MCA filings, the company has open charges of ₹40.5 Lakh on record.

Edura Pharmaceuticals Private Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-DL-06-0064317). The current compliance status is marked as compliant by the Registrar of Companies.

Company details

CIN U52311DL2010PTC206871
Registration Number 206871
Incorporation Date 09 August 2010
ROC Delhi
Listing Status Unlisted
Company Status Active
Compliance Status Active Compliant
MSME Classification Micro
Udyam Registration UDYAM-DL-06-0064317
Key People
Vikas Gambhir Director Vikas Director Rajan Vohra Director

Recognitions & Rankings of Edura Pharmaceuticals

MSME (Udyam registered) Ministry of MSME
Category
Micro (2024-25)
Udyam number
UDYAM-DL-06-0064317

Contact details

Edura Pharmaceuticals Private Limited's registered office is in New Delhi, Delhi. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Social Media
  • Registered Address
    C – 8/144 Pkt – 8 Sector – 8 Rohini, New Delhi, Delhi, India – 110085
  • Industry
    Pharma, Pharmaceutical Retailers & Distributors

To see the full contact details of Edura Pharmaceuticals Private Limited, buy the company report.

Comprehensive company report
Edura Pharmaceuticals Private Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Business activity

The main business activity of Edura Pharmaceuticals is trade. In detail, this covers wholesale trading.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
GTradeG1Wholesale Trading

To see the full business activity and turnover split of Edura Pharmaceuticals Private Limited, buy the company report.

Financials of Edura Pharmaceuticals Private Limited

FY 2025 filings available

Edura Pharmaceuticals Private Limited reported revenue of ₹5.55 Cr (down 14% YoY) for FY 2025.

Revenue · FY 2025
₹5.55 Cr ▼ 14%
Net profit · FY 2025
₹50.84 Lakh margin 9.2%
EBITDA · FY 2025
₹99.14 Lakh margin 17.9%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▼ 14%
3 years · compounded
▲ 9%
5 years · compounded
▲ 1%
EBITDA CAGR growth
1 year
▲ 22%
3 years · compounded
▲ 13%
5 years · compounded
▲ 21%

Revenue fell 14% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 1%. EBITDA rose 22% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profit and Loss Statement
Revenue from Operations
Other Income
Total Revenue
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA₹99.14 Lakh
Profit Before Tax
Tax Expense
Net Profit (PAT)₹50.84 Lakh
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profitability
EBITDA Margin17.9%
Net Profit Margin9.2%
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of Edura Pharmaceuticals Private Limited, buy the company report.

Board of directors of Edura Pharmaceuticals Private Limited

Edura Pharmaceuticals has 3 current directors and 3 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Vikas Gambhir
Also directs: Edura Infracon Private Limited
Director13 Feb 20179 Years 8 MonthsCurrent
Vikas
Also directs: Edura Infracon Private Limited
Director15 Nov 201015 Years 11 MonthsCurrent
Rajan Vohra
Also directs: Edura Infracon Private Limited
Director09 Aug 201016 Years 3 MonthsCurrent
View all directors

Peer comparison

Edura Pharmaceuticals Private Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals), with the same principal business activity (wholesale trading), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
SMB Pharma Private Limited₹5.57 Cr (FY 2025)-32.0%Bhavnagar, Gujarat, India
Saluja Distributors Private Limited₹5.57 Cr (FY 2025)-1.0%Betul, Madhya Pradesh, India
Alzey Pharmaceuticals Private Limited₹5.56 Cr (FY 2025)-21.0%Barwala, Haryana, India
R.R.R. Pharma Private Limited₹5.55 Cr (FY 2025)9.0%Chennai, Tamil Nadu, India
Edura Pharmaceuticals Private Limitedthis company₹5.55 Cr (FY 2025)₹50.84 Lakh9.2%-14.0%New Delhi, Delhi, India
Harsoria Medical Private Limited₹5.55 Cr (FY 2024)-68.0%Chandigarh, India

To see the full peer comparison of Edura Pharmaceuticals Private Limited, buy the company report.

Auditor

Edura Pharmaceuticals Private Limited is audited by S N VERMA & CO for the financial year 2019.

Auditor firmFinancial yearFirm registration number
S N VERMA & COFY 2019015107N

Shareholding

The shareholding of Edura Pharmaceuticals Private Limited is on record for 3 financial years, the latest being FY 2019, split between promoters, domestic institutions, foreign institutions, public shareholders and others.

Shareholder categoryFY 2019FY 2017FY 2016
Promoters
Domestic institutional investors (DII)
Foreign institutional investors (FII)
Public
Others

To see the full shareholding pattern of Edura Pharmaceuticals Private Limited, buy the company report.

Charges & borrowings

Open charges
₹40.5 Lakh
Satisfied charges
None
Breakdown by lending institutions
Axis Bank Limited₹0.41 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
25 Feb 2023100721327Axis Bank Limited₹20 LakhOpen
27 Jan 2022100563515Axis Bank Limited₹20.5 LakhOpen

Total charge records: 2 View all charges

MSME payment delays

No delayed payments to MSME suppliers are on our record for Edura Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

GST

Edura Pharmaceuticals has 2 GST registrations: 2 active.

Total GSTINs
2
Active
2
GSTINStateStatusRegistered on
07AACCE4729P1Z7DelhiActive01 Jul 2017
21AACCE4729P1ZHOdishaActive09 May 2019

To see the full GST registrations and return filing status of Edura Pharmaceuticals Private Limited, buy the company report.

Recent activity

Edura Pharmaceuticals Private Limited has 6 board changes on record since 2010: 3 appointments and 3 cessations. The latest: Vikas Gambhir ceased to be Additional Director on 30 Sep 2017.

AGM
Edura Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Filing
Edura Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Delhi Ii.
Charges
A charge with Axis Bank Limited amounted to Rs. 20.00 Lakh with Charge ID 100721327 was registered on 25 Feb 2023.
Charges
A charge with Axis Bank Limited amounted to Rs. 20.50 Lakh with Charge ID 100563515 was registered on 27 Jan 2022.
Ceased
Vikas Gambhir ceased to be Additional Director.
Appointed
Vikas Gambhir was appointed as Director.
Ceased
Ruby Shukla ceased to be Director.
Ceased
Rohan Vasudeva ceased to be Director.
Appointed
Vikas was appointed as Director.
Appointed
Rajan Vohra was appointed as Director.
Incorporation
09 Aug 2010
Edura Pharmaceuticals Private Limited was registered on 09 Aug 2010 with Roc Delhi Ii & aged 16 years 3 months as per MCA records.

Frequently asked questions

Edura Pharmaceuticals is an active private limited company based in New Delhi, Delhi, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 09 August 2010 (16+ years old) and is registered under CIN U52311DL2010PTC206871.

Edura Pharmaceuticals has 3 current directors:

The latest financial statements of Edura Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Edura Pharmaceuticals is 07AACCE4729P1Z7, registered in Delhi. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 21AACCE4729P1ZH (Odisha).

The CIN (Corporate Identification Number) of Edura Pharmaceuticals is U52311DL2010PTC206871. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Edura Pharmaceuticals was incorporated on 09 August 2010, making it 16+ years old. It is registered with the Registrar of Companies, Delhi.

The peers of Edura Pharmaceuticals by revenue are SMB Pharma Private Limited, Saluja Distributors Private Limited, Alzey Pharmaceuticals Private Limited, R.R.R. Pharma Private Limited, Harsoria Medical Private Limited, all in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals), with the same principal business activity (wholesale trading).

Vikas Gambhir ceased to be Additional Director on 30 Sep 2017. Vikas Gambhir was appointed as Director on 13 Feb 2017. Ruby Shukla ceased to be Director on 16 Mar 2015. Edura Pharmaceuticals has 6 board changes on record in total.

Yes, Edura Pharmaceuticals is registered as a micro enterprise under Udyam registration (number: UDYAM-DL-06-0064317).

The registered office of Edura Pharmaceuticals is at C – 8144 Pkt – 8 Sector – 8 Rohini, New Delhi, Delhi, India – 110085.

Edura Pharmaceuticals operates in the pharma industry, in the pharmaceutical retailers and distributors segment.